Voltage-Gated Calcium Channel (VGCC) Type N Antibodies
Voltage-Gated Calcium Channel (VGCC) Type N Antibodies, Serum
Test
Method
Radioimmunoassay (RIA)
Report Includes
Specimens
Serum
Clinical Utility
Voltage-Gated Calcium Channel (VGCC) Type N Antibody – N-type calcium channel antibodies are more highly associated with primary lung cancer than P/Q-type. One or all of the autoantibodies in the myasthenia gravis (MG)/LEMS evaluation can occur with neoplasia without evidence of neurological impairment. One or both calcium channel antibodies (P/Q and N) can occur with paraneoplastic and idiopathic cerebellar ataxia, encephalomyeloneuropathies, and autonomic neuropathy. Classical symptoms of LEMS include proximal muscle weakness, fatigability, dry mouth and impotence. When presentation is further complicated with oculobulbar weakness, these symptoms can easily be misinterpreted as MG. However, because VGCC antibodies are positive in only approximately 5% of MG patients, the measurement of these antibodies is very useful in distinguishing LEMS from MG.
Test Location
Quest Diagnostics, California USA
Test Version
28-Nov-2019
Specimen
Specimens
Serum
Sample Volume
1.0 mL
Minimum Volume
0.5 mL
Collection & Handling
Handling Information
Store and send frozen
Stability
Ambient | 48 hours |
---|---|
Refrigerated | 48 hours |
Frozen | 60 days |
Test Version
28-Nov-2019
Performance / Interpretation
Method
Radioimmunoassay (RIA)
Turnaround Time
14 days
Results
Name | Units | Reference Range | Conversion Factor | |
---|---|---|---|---|
Voltage-Gated Calcium Channel (VGCC) Type N Antibodies | pmol/L |
|
||
Test Location
Quest Diagnostics, California USA
Test Version
28-Nov-2019
Interface / Setup
HL7 Interface Codes
Order Code | Result Codes | Units |
---|---|---|
VGCCN S | 63126VOLTAGE GATED CALCIUM CHANNEL (VGCC)TYPE N AB | pmol/L |
Test Version
28-Nov-2019